Protalix BioTherapeutics Inc

Type: Company
Name: Protalix BioTherapeutics Inc (Protalix Biotherapeutics Inc)
First reported Aug 31 2014 - Updated Aug 31 2014 - 2 reports

Protalix jumps after FDA approval [Globes, Tel Aviv, Israel :: ]

Aug. 31--On Friday, Pfizer IncProtalix's share price rose by 8.3% on Wall Street on Friday. This follows prolonged weakness in the stock, which is down 24% over the past month."The approval of Elelyso to treat pediatric patients with Type 1 Gaucher disease ... [Published BusinessWeek - Aug 31 2014]
First reported Aug 29 2014 - Updated Aug 30 2014 - 1 reports

Protalix/Pfizer's Elelyso Approved in Pediatric Patients

ProtalixBioTherapeutics, Inc. ( PLX - Snapshot Report ) and partner Pfizer Inc. ( PFE - Analyst Report ) announced that the FDA has approved Elelyso injection for pediatric patients suffering from type I Gaucher disease. Protalix’s shares jumped ... [Published Zacks.com - Aug 29 2014]
First reported Aug 29 2014 - Updated Aug 29 2014 - 1 reports

FDA puts Pfizer superbug vaccine on fast track

The US Food and Drug Administration has agreed to undertake a speedy review of an experimental Clostridium difficile vaccine being developed by Pfizer.The jab, which is currently dubbed PF-06425090, is being tested in Phase II trials for preventing illness ... [Published Pharma Times - Aug 29 2014]
First reported Aug 28 2014 - Updated Aug 29 2014 - 6 reports

PROTALIX BIOTHERAPEUTICS : Other Events, Financial Statements and Exhibits (form 8-K)

Item 8.01. Other EventsOn August 28, 2014 , Protalix BioTherapeutics, Inc. (the "Company") and PfizerInc. ("Pfizer") issued a joint press release announcing that the U.S. Food andDrug Administration (FDA) approved ELELYSO™ (taliglucerase alfa) for in ... [Published 4 Traders - Aug 29 2014]
First reported Aug 28 2014 - Updated Aug 28 2014 - 4 reports

Sector Update: Health Care Stocks Mostly Lower; Regulators OK Expanded Use of Protalix Medication for Gaucher Disease

PFE -0.02%ABT -0.47%MRK -0.37%AMGN +0.72%Healthcare stocks were posting slim losses Thursday with the NYSE Healthcare Sector Index declining about 0.1% and shares of healthcare companies in the S&P 500 down less than 0.1% as a group.In company news, Protalix ... [Published Nasdaq - Aug 28 2014]
First reported Aug 25 2014 - Updated Aug 25 2014 - 1 reports

3 Pharma Companies That Could Deliver Breakthroughs In 'Plantibody' Technology

Companies producing so-called “plantibodies,” or plant-produced antibodies created by genetic engineering, have been attracting headlines recently.San Diego-based Mapp Pharmaceutical, which was acquired last year by Allergan (NYSE: AGN), has gotten global ... [Published Benzinga.com - Aug 25 2014]
First reported Aug 21 2014 - Updated Aug 21 2014 - 1 reports

Protalix loses half value in 1 year

Misfortunes never come singly: two days ago, after the end of trading, it was learned that the US Food and Drug Administration (FDA) had approved for marketing a competing drug for Protalix's flagship product. Yesterday, it was reported that another company ... [Published Globes - Aug 21 2014]
First reported Aug 21 2014 - Updated Aug 21 2014 - 2 reports

Research and Markets: Global Lysosomal Storage Diseases Market 2014-2018: Key Vendors are Actelion Pharmaceuticals, …

DUBLIN--(BUSINESS WIRE)--Research and Markets ( http://www.researchandmarkets.com/research/5f7fvn/global_lysosomal ) has announced the addition of the "Global Lysosomal Storage Diseases Market 2014-2018" report to their offering.The Global Lysosomal ... [Published Yahoo! Finance - Aug 21 2014]
First reported Aug 20 2014 - Updated Aug 20 2014 - 3 reports

Protalix BioTherapeutics Reaches New 12-Month Low at $2.35 (PLX)

Protalix BioTherapeutics (NYSE:PLX) shares reached a new 52-week low on Wednesday , reports. The stock traded as low as $2.35 and last traded at $2.43, with a volume of 627,535 shares trading hands. The stock had previously closed at $2.65.Separately, ... [Published American Banking News - Forex - Aug 20 2014]
First reported Aug 13 2014 - Updated Aug 13 2014 - 3 reports

Investors look to Lighten Up on Shares of Protalix BioTherapeutics, Shares Down 5.9% (PLX)

Written on Wed, 08/13/2014 - 1:14pmBy Amy SchwartzProtalix BioTherapeutics ( AMEX:PLX ) is one of today's worst performing low-priced stocks, down 5.9% to $2.69 on 1.0x average daily volume. Protalix BioTherapeutics has traded 323,000 shares thus far ... [Published Comtex SmarTrend - Aug 13 2014]
First reported Aug 11 2014 - Updated Aug 12 2014 - 2 reports

Protalix BioTherapeutics Short Interest Up 6.7% in July (PLX)

Protalix BioTherapeutics (NYSE:PLX) was the target of a large increase in short interest in July. As of July 31st, there was short interest totalling 5,921,103 shares, an increase of 6.7% from the July 15th total of 5,548,739 shares, ARN reports. Currently, ... [Published American Banking News - Aug 12 2014]
First reported Aug 04 2014 - Updated Aug 04 2014 - 1 reports

Protalix BioTherapeutics Reaches New 1-Year Low at $3.03 (PLX)

Protalix BioTherapeutics (NYSE:PLX) reached a new 52-week low on Monday , ARN reports. The company traded as low as $3.03 and last traded at $3.04, with a volume of 259,380 shares trading hands. The stock had previously closed at $3.28.Several analysts ... [Published American Banking News - Aug 04 2014]

Quotes

"The approval of Elelyso to treat paediatric patients with type 1 Gaucher disease provides physicians another treatment option for this rare and potentially debilitating disease."
...5755/$, while the shekel-euro rate is down 0.18%, at NIS 4.6971/€. RELATED ARTICLES FXCM Israel says in its market review this morning, "The shekel-dollar exchange rate rose by 4.3% in August, and signs are multiplying, both technical and fundamental, indicating that this is the start of a significant turnaround in the exchange rate trend, which has been almost uninterruptedly downwards in the past few years. The turnaround is based not only on the weakness of the shekel, but also on the strength of the dollar."
...presents during childhood," said Paige Kaplan, MB, BCh, Section of Biochemical Genetics (Metabolic Diseases), Children's Hospital of Philadelphia. "It is important that children with this disease have access to a range of FDA-approved treatment options that are effective."
"The approval of Elelyso to treat paediatric patients with type 1 Gaucher disease provides physicians another treatment option for this rare and potentially debilitating disease,” said Rory O Connor, senior vice president, global medical affairs, Global Innovative Pharma Business, Pfizer Inc. “This paediatric indication, along with the recent announcement that Elelyso received kosher certification by the Orthodox Union (OU), reinforces the ongoing commitment of Pfizer to addressing the needs of the Gaucher community.”"

More Content

All (76) | News (56) | Reports (0) | Blogs (7) | Audio/Video (0) | Fact Sheets (2) | Press Releases (10)
sort by: Date | Relevance
Mon: Gazit-Globe leads market gains [Published Globes - 5 hours ago]
UBS: Teva hiked Copaxone price 9.9% [Published Globes - 7 hours ago]
Pfizer and Protalix’s Elelyso receives FDA appr... [Published Pharmaceutical Technology - 10 hours ago]
Debt settlement gives IDB NIS 1.7b Q2 profit [Published Globes - 11 hours ago]
Shekel-dollar rate resumes climb [Published Globes - 11 hours ago]
Protalix jumps after FDA approval [Globes, Tel ... [Published BusinessWeek - Aug 31 2014]
Sun: Banks drag market down [Published Globes - Aug 31 2014]
Protalix jumps after FDA approval [Published Globes - Aug 31 2014]
US FDA approves Elelyso for injection for paedi... [Published PharmaBiz - Aug 30 2014]
Protalix/Pfizer's Elelyso Approved in Pediatric... [Published Zacks.com - Aug 29 2014]
FDA approves Elelyso for pediatric use in Gauch... [Published Pharma Letter - Aug 29 2014]
PROTALIX BIOTHERAPEUTICS : Other Events, Financ... [Published 4 Traders - Aug 29 2014]
FDA approves Pfizer and Protalix's Elelyso to t... [Published PBR - News - Aug 29 2014]
FDA puts Pfizer superbug vaccine on fast track [Published Pharma Times - Aug 29 2014]
Protalix Announces Conference Call to Discuss E... [Published GlobeNewswire: Nonprofit News - Aug 28 2014]
Protalix Announces Conference Call to Discuss E... [Published EMoneyDaily - Aug 28 2014]
Sector Update: Health Care Stocks Mostly Lower;... [Published Nasdaq - Aug 28 2014]
Pfizer and Protalix BioTherapeutics Announce FD... [Published PharmaceuticalProcessing - Aug 28 2014]
Why Protalix BioTherapeutics (PLX) Stock Is Sur... [Published TheStreet.com - Aug 28 2014]
Why Protalix BioTherapeutics (PLX) Stock Is Sur... [Published The Street Latest - Aug 28 2014]
Protalix BioTherapeutics Up 6.6%, Shares Break ... [Published Individual.com - Aug 28 2014]
Pfizer and Protalix BioTherapeutics Announce FD... [Published Scottrade - Aug 28 2014]
Pfizer and Protalix BioTherapeutics Announce FD... [Published Business Wire Health News - Aug 28 2014]
3 Pharma Companies That Could Deliver Breakthro... [Published Benzinga.com - Aug 25 2014]
Protalix loses half value in 1 year [Published Globes - Aug 21 2014]
Research and Markets: Global Lysosomal Storage ... [Published Yahoo! Finance - Aug 21 2014]
Global Lysosomal Storage Diseases Market 2014-2... [Published Individual.com - Aug 21 2014]
Protalix BioTherapeutics Reaches New 12-Month L... [Published American Banking News - Forex - Aug 20 2014]
Protalix BioTherapeutics Down 7.5%, Shar... [Published Financial News Network online - Aug 20 2014]
Protalix BioTherapeutics Down 7.5%, Shares Slid... [Published Individual.com - Aug 20 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
FDA approves Pfizer and Protalix's Elelyso to t... [Published PBR - News - Aug 29 2014]
The US Food and Drug Administration (FDA) has granted approval for Pfizer and Protalix BioTherapeutics' Elelyso (taliglucerase alfa) for injection to treat adult and pediatric patients with confirmed diagnosis of Type 1 Gaucher disease. ...
Pfizer and Protalix BioTherapeutics Announce FD... [Published Business Wire Health News - Aug 28 2014]
NEW YORK & CARMIEL, Israel--(BUSINESS WIRE)--Pfizer Inc. (NYSE:PFE) and Protalix BioTherapeutics, Inc. (NYSE-MKT:PLX, TASE:PLX) announced today that the U.S. Food and Drug Administration (FDA) approved ELELYSO™ (taliglucerase alfa) for injection for pediatric ...
2nd Quarter Executive Turnover Remains Positive... [Published Management Turnover as Change Agent - Jul 17 2014]
Executive turnover continues in a positive direction despite a slowdown in a few of the key categories.  The trend in executive turnover continues to correlate with the continuing positive news related to job growth in the American economy and the declining ...
Research and Markets: Nerve Gas & Pesticide Poi... [Published Business Wire Manufacturing News - May 28 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/zsmp3h/nerve_gas_and) has announced the addition of the "Nerve Gas & Pesticide Poisoning - Pipeline Review, H1 2014" report to their offering. This report provides ...
Research and Markets: Nerve Gas & Pesticide Poi... [Published Business Wire Health News - May 28 2014]
DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/zsmp3h/nerve_gas_and) has announced the addition of the "Nerve Gas & Pesticide Poisoning - Pipeline Review, H1 2014" report to their offering. This report provides ...
1 2

Press Releases

sort by: Date | Relevance
Protalix Announces Conference Call to Discuss E... [Published GlobeNewswire: Nonprofit News - Aug 28 2014]
Protalix Announces New Data on ELELYSO(TM) (tal... [Published GlobeNewswire: Advertising News - Jun 27 2014]
Protalix BioTherapeutics Announces New Data on ... [Published GlobeNewswire: Advertising News - Jun 23 2014]
Protalix BioTherapeutics Initiates Phase II Stu... [Published GlobeNewswire: Advertising News - Jun 18 2014]
Protalix BioTherapeutics' President and Chief E... [Published GlobeNewswire: Acquisitions News - Jun 13 2014]
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.